Index  by unknown
INDEX
A
Absolute claudication distance, initial claudication distance
v, s112
Acetylsalicylic acid, s209-21O
Activated partial thromboplastin time, s56
Activated protein C/ resistance to/ assay for, s56
Acute limb ischaemia
aetiology of, s115
anatomic improvement in, s125-126
anticoagulant therapy in, s129
catheter-directed thrombolysis v surgical revascularisation
in, s133
classification system for, s123
clinical categories of, s122
clinical classification of, s123
clinical outcomes in, sl25
clinical presentation of, s115-116
clinical trial issues in/ s140--143
combining treatments within trial groups in, s142
conditions mimicking, s117-118
definition of, s115
diagnosis of, urgency of, s124
differential diagnosis of, s117-119
economic aspects of, s140
effectiveness assessment in, s126-127
endovascular procedures for, s129-131
factors for intervention selection in, s130
follow-up care in, s137
functional status in, s127
health-related quality of life in, s127
haemodynamic improvement in, s125-126
imaging in/ s121
immediate management of, s128-129
management algorithm for, s138, s139
motor function loss in, s117
outcome assessment methodology in, s124-127
patient history in, s116
perioperative angiography in, s132
physical examination in, sl16-117
predicting outcome in, s123
procedural morbidity in, s126
procedural mortality in, s126
sensory function loss in, s117
severity levels in, s122-124
subcutaneous heparin in, s129
surgery in, s132-135
surgical technique in, s132
symptom recurrence in, s127
technical therapy success in, s125
therapeutic options in, s135
therapy of, s128
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therapy success reportage in, s127
thrombolysis following arteriography in, s130
treating underlying lesion in, s136-137
treatment crossovers in, s142
trial cost-effectiveness analysis in, s143
trial end point selection in, s142-143
trial entry criteria in, s141
trial failures in, s141
trial intention-to-treat rule in, s141
trial standardising reporting practices in, s142
trial stratification treatment groups in, s141-142
Age
critical limb ischaemia and, s20
intermittent claudication and, s89, s9
Ambulation, s223
Aminophylline, s79
Amputation
as clinical trial end point, s240
cost of, s235-236
incidence of, s19, s22
indications for, s225-226
level of, s23-24
numbers of, s26
primary, s226-227, s235-236
risk factors for, s22-23
secondary, s226
selection of, s226-228
technical principles of, s228
Amputee, fate of, s24
Anaesthesia, s200
Aneurysm, thrombosed popliteal, management of, s137-138
Angiogenesis, gene-induced therapeutic, in critical limb isch-
aemia/ s170--171
Angiography, s216
alternatives to/ s62
in intermittent claudication, s61
perioperative, s132
Ankle pressure, in critical limb ischaemia, s153
Ankle pressure measurement, s57-58
Ankle pulse
detection of, s5-6
intermittent claudication and, and ankle-brachial pressure
index, s6
Ankle-Brachial Pressure Index, s58, s2.15
cardiovascular disease and, s13
claudication progression and, sl5-16
in critical limb ischaemia, s162
intermittent claudication and, and pulse, s6-7
measurement of, s6-7
Antibiotics, s200
in ulcer therapy, s166
Anticardiolipin antibody nssay, s56
Index 8245
Anticoagulant, 5210
in critical limb ischaemia, 5170
Anticoagulation, long-term, following thromboembo-
lectomy, 5137
Antiphospholipid antibodies, test for, s56
Antiphospholipid syndrome, s55, 556
Antiplatelet therapy, s70-71, s78-79, s209-21O
in critical limb ischaemia, 5169-170
Antithrombin assay, 556
Antithrombin deficiency, 555
Aortobifemoral bypass, s174
patency following, 598
Aortoiliac disease
endovascular treatment of, 5182
preferred therapeutic options for, s183
surgical treatment of, 5174-179
Aortoiliac endarterectomy, 5174
Aortoiliac percutaneous transluminal balloon angioplasty,
s83-86
Aortoiliac reconstruction, 5202-204
Aortoiliac stent, 586-87
indications for, 587
Arterial dissection, s119
Arterial thrombosis, due to hypercoagulable state, 5119
Arterial trauma, 5119
Arteriovenous fistula, 5187
Arteritis, 5119
Arthritis, of hip, differential diagnosis of, 551
Atheroembolism,s118
Atherosclerosis
evaluation for, 557
systemic, progression and, 516-18
Axillobifemoral bypass, 598
Axillofemoral bypass, 5176
Axillounifemoral bypass, 5179
B
Baker's cyst, symptomatic, differential diagnosis of, 551
BasIc study, 514
Beraprost, 577, 578
Biochemical study, in intermittent claudication, 554-57
Blood, ultraviolet irradiated autologous, 5222
Blood lipid study, in intermittent claudication, 554-55
Buerger's disease, 552, 5158, 5160
Buflomedil, 576, 577
Buttock, differential diagnosis of, 551
C
Calf, intermittent claudication of, differential diagnosis of,
551
Cancer-associated thrombosis, 555
Capillary microscopy, in critical limb ischaemia, 5153-15-1
Cardiovascular disease
ankle-brachial pressure index and, 513
peripheral arterial disease and, 513
Cardiovascular morbidity prevention trial; in intermittent
claudication, 5114
Cardiovascular mortality prevention trial, in intermittent
claudication, 5114
Carnitine, 580
Catheter-directed thrombolysis, surgical revascularisation v,
in acute limb ischaemia, 5132-133
Causalgia, s158
Cerebrovascular disease, peripheral arterial disease and, s13
Chelation therapy, s223
Chronic compartment syndrome, s50
differential diagnosis of, 551
Chronic critical limb ischaemia
definition problems in, s145-146
historical background in, 5144-145
nomenclature in, 5144
proposed definition of, 5146
Chronic subcritical ischaemia, s146
Cigarette smoking, s68-69
Cilostazol, s76-77, s78
Cinnarizine, 577
Claudicant, s47
coronary artery disease in, s18
fate of, 518
five-year fate of, 519
Claudication, s47
Claudicator, 5-17
Clinical trial
additional variables in, s242
adjuvant pharmacotherapy in, 5242
constant v graded treadmill exercise protocol in, s112
design of, in critical limb ischaemia, 5238
end point selection in, s142-143
end points for, 5112-114
entry criteria in, s242
inclusivity v exclusivity in, s110, 5238-240
operator variability in, 5241-242
outcome reporting timing in, s240-241
patient stratification in, s239-240
patients entered in, 5242
possible primary end points in, of critical limb ischaemia,
s240-241
quality of life measurements in, sl13-114
secondary end points in, sl13
secondary interventions in, s242-243
standardising reporting practices in, s142
statistical v clinical significance in, s113
stratification in, s111-112
stratification treatment groups in, s141-142
treatment crosssovers in, s142
Coarctation, claudication due to, s52
Colour flow duplex scanning, s215-216
in intermittent claudication, s61-62
Conduit, choice of, s185-186
Consensus process
caveat for, s3-4
essential criteria for, sl
history of, s1
methodology of, 51, s3
objectives of, sl-2
Coronary artery disease
in claudicants, s18
peripheral arterial disease and, sI2-13
Coronary Artery Surgery Study, s17
Cost(s)
of critical limb ischaemia therapy, s232-236
of diagnostic procedures, s232
fixed, s-11
health care, s-10-41
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intangible, 541
opportunity, 541
semi-fixed,s41
tangible non-health care, 541
variable, 541
Cost data
collection of, 540
computation of, s4D-42
Cost minimisation analysis, s42
Cost-benefit analysis, 542-43
Cost-effectiveness, in intermittent claudication
of antiplatelet therapy, 5106-107
of lipid control, 5107
Cost-effectiveness analysis, 542
Cost-utility analysis, 542
Coumarin, 5210
in acute limb ischaemia, 5137
Cramps, night, 5158
Critical limb ischaemia
age and, 520
ankle pressure in, 5153
basic treatment of, 5164-167
cardiovascular events in, 5243
changing outcome of, 521-22
clinical definition of, 5146
clinical trial issues in, 5237-243
contralateral leg in, 5243
current criteria for, high-risk patients not covered by, 5146
diabetes and, 520
diagnostic evaluation in, objectives for, 5156
differential diagnosis of, 5157-160
economic aspects of, 5232-236
effectiveness measures in, 5162-163
foot care in, 5165
history of, 5150-151
imaging in, 5154
incidence of, 519
interventional options in, risks of, 5154-155
interventional treatment of, 5173
investigations for, s152-156
life-threatening coexisting disease therapy in, 5165
management algorithm for, 5231
management plan in, 5148-150
microcirculatory investigations in, 5153-154
microcirculatory pathophysiology in, 5147-148
multidisciplinary team approach in, 5149
outcome assessment methodology in, 5161-163
patient audits in, 5149-150
patient fate in, 521, 522, 523
patient management costs in, 5236
pharmacotherapy for, 5167-171
physical examination in, 5151-152
prevalence of, 519
prognosis in, 5146-147
progression of, 5238
reporting standards definition of, 5146
risk factor control in, 5166-167
risk factors for, 520
risks odds ratio in, for mortality, 520
secondary interventions in, 5242-243
smoking and, 520
sympathectomy, 5224
testing for, 5152-153, s154
toe pressure in, s153
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treatment of, 5163-167
trial secondary end points in, s241
Crossover bypass graft, long-term results of, 5179
Cyclosporin, 5212
Cyst, popliteal, 5119
D
Decision modelling, in peripheral arterial disease therapy,
544-45
Defibrinogenating agent, in critical limb ischaemia, 5170
Defibrotide, 579
Descriptive instrument, 533
Dextran, 577, 5210-211
Diabetes mellitus, 5201
claudication progression and, 515
critical limb ischaemia and, 520, 5166-167
foot in, 5148
intermittent claudication and, 549
neuropathic ulcer of, s159
peripheral arterial disease and, 59, 569
Diabetic neuropathy, s157
Diabetic patient, evaluating, considerations in, 559
Diagnosis-Related Group, reimbursement schedule for, 542
Dilute Russell Viper Venom Test, s56
Doppler arterial studies, 5120
Doppler pressure measurement, 5227
Doppler velocity wave form analysis, 559-60
Duplex scanning, 5121
Dysfibrinogenaemia, 555
E
Economic evaluation
limitations of, s43-44
of peripheral arterial disease therapy, s39-45
principles of, 539-40
Edinburgh questionnaire, diagnostic performance of, 55
Embolus(i)
in acute limb ischaemia, 5115-116
atherosclerotic plaque disruption cholesterol, 5118
peripheral, claudication due to, 552
Endovascular procedure
in acute limb ischaemia, s132-133
complications of, s94-95
Epidural spinal cord stimulation, 5223
Ergotism, s119
Erythrocyte sedimentation rate, in intermittent claudication,
555
Euglobulin lysis time, 556
EuroQol, 536-37
Exercise
rehabilitation with, s71-73
unsupervised, 5101
External iliac dysplasia, claudication due to, 552
F
Factor V Leiden, assay for, 556
Factor V Leiden mutation, s55
Index 8247
Factor XI[ deficiency, 555
Fasciotorny, in acute limb ischaemia, 5136
Femorofemoral bypass, 5179
Femoropopliteal angioplasty, 5192-194
Fernoropopliteal bypass
above-knee, vein v prosthetic grafts for, s99
conduit for, s99
Femoropopliteal bypass graft, s189
Femoropopliteal lesion
interventional treatment of, 590
morphological stratification of, s88
Femoropopliteal percutaneous translurninal balloon an-
gioplasty, 588-91
Femoropopliteal stent, 590, s93
patency of, 591-92
Fibrinogen, peripheral arterial disease and, sl1
Fixed cost, s41
Fonatine stage, of peripheral arterial disease, 534
Foot
in diabetes, s148
intermittent claudication of, 551
ulcer of, s158
Framingham study, 514-15
Functional status
in acute limb ischaemia, s127
improvement in, s163 .
Functional status assessment, 535
in intermittent claudication, s60
G
Gamble, standard, 536
Gmft
failed, s201
proximal, 5232
Graft surveillance, appropriate use of, 5216-218
H
Health Utility Index, s36-37
Haematologic study, in intermittent claudication, s54-57
Haernodilution, in critical limb ischaemia, 5170
Heparin, 5210
subcutaneous, in acute limb ischaemia, s129
Heparin-induced thrombocytopenia, 556
Hexopal, 577
Hip
arthritis of, 551
osteoarthritis of, 550-51
Homocysteine, in peripheral arterial disease, 570
Hormone replacement therapy, 570
Hyperbaric oxygen, 5222
Hypcrcoagulability, peripheral arterial disease and, 511
Hypercoagulable state
intermittent claudication and, 549
in peripheral arterial disease, 570
types of, 555
Hypcrhomocysteinemia, 555, 570
peripheral arterial disease and, 511
Hyperlipldaernia
in critical limb ischaemia, s167
intermittent claudication and, 549
peripheral arterial disease and, 510-11, 569
Hypertension
claudication progression and 516
in critical limb ischaemia, s1(~6
intermittent claudication and, 549
in peripheral arterial disease, 570
peripheral arterial disease and, sID
Hypoplastic aorta, 5177
Iliac artery occlusion, 585
Iliac artery stenosis, endovascular therapy of, patency rates
for, 585
Iliac lesion
interventional management of, 584
morphological stratification of, 583
Iliac to femoral bypass, 5179
Imaging, in intermittent claudication, s61-{)2
Impaired glucose tolerance, peripheral arterial disease and,
59
Infrainguinal bypass graft, 5188, 5189
Infrainguinal disease, 5177-178, 5192-196, 5198-200
surgical therapy of, 5184-189
Infrainguinal vein bypass grafting, s204-205
Infrapopliteal percutaneous transluminal balloon anglo-
plasty, 594
Initial claudication distance, absolute claudication distance
v, 5112
Insulin resistance, peripheral arterial disea se and, 59
Intangible cost, 541
Intention-to-treat rule, 5141
Intermittent claudicant, definition of, 5146
Intermittent claudication
absolute vinitial claudication distance in, 5112
by nge group, 58, 9
ankle-brachial ~ressure index and, 56-7
antiplatelet therapy in, cost-effectiveness of, 5106-107
asymptomatic, prevalence of, 58-9
background treatment of, 5110-111
cardiovascular morbidity prevention trials in, 5114
cardiovascular mortality prevention trials in, 5114
clinical assessment of, s5-{),548-54
clinical measures in, s65
clinical trial guidelines for, slO8-109
clinical trial objectives in, s109
clinical trial reporting standards for, 5109
clinical v quality-of-life outcomes in, s64-{)6
constant v graded treadmill exercise protocol in, 5112
death in, causes of, 517
defining, problem with, 54
definition of, s47
diagnostic strategies for, 5104-105
differential diagnosis of, 549-50, 551
economic aspects of, 5104
endovascular procedures for, s82-95
genetic risk for, 512
grading pulses in, 553
haemodynamic abnormalities in, s47-48
history in, 548-49
imaging techniques in, s61-{)2
incidence of, 57
invasive therapy in, indications for, s68
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lipid control in, cost-effectiveness of, s107
management algorithm for, s73
medical treatment of, s104
in men, slO
mortality of, sl6-17
natural history of, s110
nomenclature for, s47
nonfatal cardiovascular events in, s16
overall strategy in, s66-68
patient characteristics in, 547
patient-based outcomes parameters in, 565-66
pharmacotherapy for, s76-81
physical examination for, s52-54
prevalence of, s7-8
progression from, to peripheral arterial disease, s68
progression of, sl4-15
protective factors for, sl1
quality of life measurements in, s64, s65, 5113-114
risk factor odds ratios for, s12
risk factors for, 59-12, s49
routine tests for, s54-58
smoking and, s9-11
statistical v clinical significance in, 5113
surgery for, s97-100
therapeutic options for, s100-102
treatment algorithm for, s103, s104
treatment costs for, s105-106
trial end points in, s112-114
trial secondary end points in, sl13
walking test in, s111
worsening of, s14-15
Intimal hyperplasia, agents to inhibit, s212
Intramuscular gene transfer, in critical limb ischaemia, 5171
Isovolaemic haemodilution, s79
J
[uxtarenal aortic occlusion, s177
K
Ketanserin, s79, s212
L
L-arginine, s81, s212
Laser Doppler fluxmetry, in critical limb ischaemia, s153
Leg, ulcer of, differential diagnosis of, s158
Limb salvage, following chronic critical limb ischaemia ther-
apy, s162
Lipid study, blood, in intermittent claudication, s54-55
Lumbar spine, osteoarthritis of, s50
Lupus anticoagulant, s56
M
Magnetic resonance angiography, s121
in intermittent claudication, s62
Malnutrition, s55
McMaster Health Index Questionnaire, slO1
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Medical Outcome Study Short-Form 36, s35
Meta-analysis, in peripheral arterial disease therapy, s44-45
Metabolic syndrome, peripheral arterial disease and, s9
N
Naftidrofuryl, s76, s77
Naroparcil, s212
Negative pressure application, s223
Nephrotic syndrome, s55
Nerve root compression, s157-158
differential diagnosis of, 551
Neuroischaemic ulcer, s159
Neuropathic ulcer, s159
Night cramp, s158
Nitric oxide, s148, s211
o
Obesity, s69
Occlusive arterial lesion, causes of, s52
Opportunity cost, s41
Osteoarthritis
of hip, s50-51
of lumbar spine, s50
Outcome measure(s)
objective, s33-34
symptomatic, s34, s65
Outcomes, efficacy measures for, s30-32
Outcomes research, in peripheral arterial disease, s30-37
Oxygen, hyperbaric, s222
P
Pain, control of, in critical limb ischaemia, s164-165
Patency
assisted primary, s32-33
definition of, s37
determination of, s37
primary, s32-33
Pentoxifylline, s76, s77
Perceived health, s35
Percutaneous aspiration thrombectomy, s130
Percutaneous mechanical thrombectomy, s131
Percutaneous transluminal balloon angioplasty, s82-83
aortoiliac, 583-86
surgery v, 5101-102
Peripheral arterial claudication, coexisting risk factors for,
sl1
Peripheral arterial disease
catheter intervention in, s82-83
classification of, s34
claudication due to, s52
coexisting vascular diseases and, s12-14
diabetes and, s9, 569
efficacy measures in, s31
epidemiology of, s4
fibrinogen and, 511
haernodynarnic abnormalities in, s47-48
hypercoagulability and, sl1
hyperhomocysteinemia and, sl1
Index 8249
hyperlipidaemia and, s1()-11
hypertension and, slO
metabolic abnormalities of, s48
neurological abnormalities of, s48
outcomes research in, s3()-31
risk factors for, s9-12
smoking and, s9-11, s69
Peripheral arterial disease
therapy decision modelling in, s44-45
economic aspects of, s39-45
economic evaluation limitations in, s43-44
meta-analysis in, s44-t5
procedural complications of, s32
success criteria for, s32-33
technical success of, s31-32
Peripheral nerve pain, s50
Peripheral sensory neuropathy, s158
Persistent sciatic arteries, claudication due to, s52
Plasma fibrinogen level, s56
Plasminogen
abnormal, s55
deficiency of, s55
level of, s56
Plasminogen activator deficiency, s55
Platelet aggregation test, s56
Platelet count, s56
Platelet reactivity, abnormal, s55
Popliteal aneurysm, thrombosed, management of, s137-138
Popliteal artery aneurysm, thrombosed, s119
Popliteal artery segment, isolated, s185
Popliteal cyst, s119
claudication due to, s52
Popliteal entrapment, s119
claudication due to, s52
Procedural mortality, definition of, s162
Propionyl-L-camitine, s77, s78
Prostacyclin, s148
Prostaglandin, s80
Prostanoid, s80, s211
in critical limb ischaemia, s167-169
Prosthetic graft, surveillance of, s216-218
Protein C assay, s56
Protein C deficiency, s55
Protein S assay, s56
Protein S deficiency, s55
Protein-losing enteropathy, s55
Prothrombin mutation, s55
Prothrombin time, s56
Proximal revascularisation, s183-184
Pseudoxantoma elasticum, claudication due to, s52
Psychological well-being, s35
Pulses
absent, s5-6
in acute limb ischaemia, s117-119
grading, for intermittent claudication, s53-54
intermittent claudication and, s5-{j
peripheral, detection of, s5-6
Pulse volume recording, s59
Q
Quality-adjusted life year, s36
Quality of life
assessment of, s35
in critical limb ischaemia, s241
improvement in, s162-163
in intermittent claudication, s64, s65
valuing health-related, s36-37
Quality of Well-Being Scale, s36-37
Questionnaire
disease-specific health status, s34
Edinburgh, s5
generic health status, s35-36
for intermittent claudication detection, s4-5
WHO-Rose, s4-5
R
Radionuclide perfusion scan, in critical limb ischaemia, s153
RAND-36, s35
Reflex sympathetic dystrophy, s157
Reperfusion injury, s136
Revascularisation, surveillance following, s214-219
Role function evaluation, s35
Rutherford category, of peripheral arterial disease, s34
s
Segmental limb systolic pressure measurement, s51>-59
Segmental plethysmography, s59
Semi-fixed cost, s41
Sensory neuropathy, diabetic, s157
Short Form 36, s35, s65
Short-term morbidity, definition of, s162
Skin perfusion pressure management, s227-228
Smoking
cessation of, in critical limb ischaemia, s166
claudication progression and, sIS
critical limb ischaemia and, s20
intermittent claudication and, s9-11
peripheral arterial dis ease and, s9-11, s69
Spinal cord compression, s50
differential diagnosis of, s51
Spinal cord stimulation, epidur~1, .s223 . . .
Spiral computed tomography, In intermittent claudication,
s62
Standard gamble, s36
Stent, s207-208
multiple, cost-effectiveness of, s87
proximal, s232
STILE trial, s133-134
major findings of, s134
Stress test, alternative, s60
Summary receiver operating charact:ristic curve, s44-t?
Surgical rcvascularisation, catheter-directed thrombolysis v,
in acute limb ischaemia, s133
Sympathectomy
in acute limb ischaemia, s121
in critical limb ischaemia, s224
lumbar, indications for, s224
T
Thigh, differential diagnosis of, s51
Thoracofcmoral bypass, s176
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S250
Thrombin time, s56
Thromboangitis obliterans, see Buerger's disease
Thrombolysis
in acute limb ischaemia, sI29-130
contraindications to, s130
high-dose systemic, in arterial occlusion, s130
Thrombophilia, s55
Thrombosis
in acute limb ischaemia, sl15-116
arterial, due to hypercoagulable state, s119
graft, s137
Ticlopidine, s77, s78, s210
Time trade-off, s36
Tobacco abuse, intermittent claudication and, s49
Toe pressure, in critical limb ischaemia, s153
TOPAS trial, s134-135
Transcutaneous oxygen measurement, s227
in critical limb ischaemia, s153
Trousseau's thrombosis, s55
U
Ulcer(s)
associated with haematologic disease, s160
diabetic neuropathic, s159
aetiological classification of, s158
foot, differential diagnosis of, s158
healing of, s240
leg, s158
systemic therapy of, s166
topical therapy of, s165-166
treatment of, s165-166
venous, s159
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Index
Ultraviolet irradiated autologous blood, s222
v
Valuational instrument, 533
Valuational measure, s33
Variable cost, s41
Vascular endothelial growth factor, s80
in critical limb ischaemia, 5171
Vascular registry
advantages of, 5221
problems with, 5220-221
Vasculitis, 5160
Vasoactive drug(s)
in acute limb ischaemia, 5129
in critical limb ischaemia, s170
Vasodilntor,s79
Vein bypass graft, surveillance of, 5216-218
Venous claudication, s50
differential diagnosis of, s51
Venous compression, intermittent, s223
Venous cuff, 5187
Venous ulcer, 5159
Verapamil, s77, s79
Vitamin E, 579
W
Walking, 5223
Walking distance, 565
Walking test, in intermittent claudication, 5111
WHO-Rose questionnaire, diagnostic performance of, 54-5
